We are live on !
Find out more
HighMark Wealth Management Portfolio holdings
AUM
$299M
Turnover
13.67%
1-Year Est. Return
53.01%
This Fund
S&P 500
This Quarter Est. Return
+21.77%
1 Year Est. Return
+53.01%
3 Year Est. Return
+109.68%
5 Year Est. Return
+113.63%
10 Year Est. Return
–
AUM
$299M
AUM Growth
+$52.9M
(+22%)
Cap. Flow
+$8.26M
Cap. Flow % of AUM
Cap. Flow %
2.77%
Top 10 Holdings %
Top 10 Hldgs %
65.82%
Holding
600
New
46
Increased
156
Reduced
94
Closed
36
Avg Time Held
Equity + Options
3.4
years
Top 10 Avg Time Held
Equity + Options
2.7
years
Top 20 Avg Time Held
Equity + Options
2.3
years
Avg Time Held Equity only
3.4
years
Top 10 Avg Time Held Equity only
2.7
years
Top 20 Avg Time Held Equity only
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity MSCI Health Care Index ETF
FHLC
|
+$18.3M |
| 2 |
SI-BONE Inc
SIBN
|
+$3.79M |
| 3 |
Duos Technologies
DUOT
|
+$2.91M |
| 4 |
Apogee Therapeutics
APGE
|
+$2.91M |
| 5 |
Neuropace
NPCE
|
+$1.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$9.41M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$5.14M |
| 3 |
AnaptysBio
ANAB
|
+$3.29M |
| 4 |
iShares MSCI EAFE Value ETF
EFV
|
+$1.64M |
| 5 |
Piper Sandler
PIPR
|
+$1.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 64.9% |
| 2 | Healthcare | 21.84% |
| 3 | Technology | 4.77% |
| 4 | Financials | 3.58% |
| 5 | Industrials | 1.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
401
GrowGeneration
GRWG
$89M
| $4.44K | ﹤0.01% |
3,000
| – | – |
2025 Q2
4 quarters
|
|
402
iShares Core MSCI Total International Stock ETF
IXUS
$57.1B
| $4.39K | ﹤0.01% |
46
| – | – |
2023 Q1
13 quarters
|
|
403
Riot Platforms
RIOT
$4.44B
| $4.38K | ﹤0.01% |
160
| – | – |
2019 Q4
26 quarters
|
|
404
eBay
EBAY
$53.1B
| $4.36K | ﹤0.01% |
39
| – | – |
2025 Q4
2 quarters
|
|
405
Accenture
ACN
$160B
| $4.36K | ﹤0.01% |
35
+15
| +75% | +$2.6K |
2026 Q1
1 quarter
|
|
406
e.l.f. Beauty
ELF
$6.53B
| $4.32K | ﹤0.01% |
58
| – | – |
2022 Q3
15 quarters
|
|
407
BioMarin Pharmaceuticals
BMRN
$11.1B
| $4.29K | ﹤0.01% |
75
| – | – |
2021 Q3
19 quarters
|
|
408
Alnylam Pharmaceuticals
ALNY
$21.2B
| $4.21K | ﹤0.01% |
14
| – | – |
2025 Q4
2 quarters
|
|
409
D-Wave Quantum Inc
QBTS
$3.83B
| $4.2K | ﹤0.01% |
175
+10
| +6% | +$219 |
2025 Q1
5 quarters
|
|
410
Omnicell
OMCL
$1.66B
| $4.15K | ﹤0.01% |
100
| – | – |
2019 Q4
26 quarters
|
|
411
Sundial Growers
SNDL
$311M
| $4.05K | ﹤0.01% |
3,000
| – | – |
2025 Q2
4 quarters
|
|
412
Occidental Petroleum
OXY
$60.7B
| $4.03K | ﹤0.01% |
83
| – | – |
2023 Q2
12 quarters
|
|
413
CenterPoint Energy
CNP
$28.3B
| $4.01K | ﹤0.01% |
+91
| New | +$3.9K |
2026 Q2
0 quarters
|
|
414
ServiceNow
NOW
$110B
| $3.97K | ﹤0.01% |
92
+47
| +104% | +$4.65K |
2019 Q4
26 quarters
|
|
415
ARK Blockchain & Fintech Innovation ETF
ARKF
$725M
| $3.95K | ﹤0.01% |
100
| – | – |
2025 Q2
4 quarters
|
|
416
Allstate
ALL
$66.8B
| $3.92K | ﹤0.01% |
16
| – | – |
2024 Q3
7 quarters
|
|
417
Ocular Therapeutix
OCUL
$1.48B
| $3.9K | ﹤0.01% |
397
| – | – |
2019 Q4
26 quarters
|
|
418
SLB Ltd
SLB
$77.2B
| $3.89K | ﹤0.01% |
84
-33
| -28% | -$1.77K |
2022 Q3
15 quarters
|
|
419
CoreWeave
CRWV
$27.7B
| $3.88K | ﹤0.01% |
39
-15
| -28% | -$1.62K |
2025 Q3
3 quarters
|
|
420
Constellation Brands
STZ
$23.8B
| $3.76K | ﹤0.01% |
27
+25
| +1,250% | +$3.72K |
2019 Q4
26 quarters
|
|
421
NatWest
NWG
$62.3B
| $3.76K | ﹤0.01% |
213
-89
| -29% | -$1.43K |
2024 Q4
6 quarters
|
|
422
Gevo
GEVO
$289M
| $3.75K | ﹤0.01% |
2,500
| – | – |
2020 Q3
23 quarters
|
|
423
Kimberly-Clark
KMB
$36B
| $3.73K | ﹤0.01% |
+34
| New | +$3.37K |
2026 Q2
0 quarters
|
|
424
iShares MSCI India ETF
INDA
$5.95B
| $3.73K | ﹤0.01% |
76
| – | – |
2024 Q3
7 quarters
|
|
425
PayPal
PYPL
$48.8B
| $3.64K | ﹤0.01% |
84
| – | – |
2019 Q4
26 quarters
|
|
Similar funds
BOC
HighMark Wealth Management's Q2 2026 Portfolio in Review
As of Q2 2026, HighMark Wealth Management held 600 positions worth $299M, up 22% from $246M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
HighMark Wealth Management's Q2 2026 filing shows 46 new, 156 increased, 94 reduced and 36 closed positions. Its largest new stake was Duos Technologies: 289,884 shares worth $3.48M. The largest sale was Centessa Pharmaceuticals, an estimated $9.41M.
By sector, the portfolio is most concentrated in Miscellaneous at 65% of assets, down from 65% a quarter earlier, followed by Healthcare and Technology.
- HighMark Wealth Management's largest Q2 2026 buy was Duos Technologies: 289,884 shares worth $3.48M.
- HighMark Wealth Management added most to Fidelity MSCI Health Care Index ETF in Q2 2026, an estimated $18.3M increase.
- HighMark Wealth Management's biggest Q2 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $5.14M.
- HighMark Wealth Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $9.41M.
- HighMark Wealth Management's ten largest holdings make up 66% of its $299M portfolio in Q2 2026.
- HighMark Wealth Management opened 46 new positions and closed 36 in Q2 2026.
- HighMark Wealth Management's portfolio value rose 22% quarter-over-quarter to $299M.
Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.